AstraZeneca stock dives 9% after heart drug trial misses target
business
According to CNBC, AstraZeneca stock dropped nine percent after the company's heart drug trial missed its target.
Source: https://www.cnbc.com/2026/07/09/astrazeneca-stock-trial-h...
Listen to this story
Hear this and more stories in a personalized audio briefing.
Open The Chonkerton